This move addresses conflict of interest concerns. It mirrors a similar separation at Samsung Biologics. The foundry business makes chips for other firms. Concerns exist about technology leaks to ...

16 for final approval. Samsung Biologics explained that the split will allow the company to concentrate resources on its CDMO business, which operates under a different revenue model compared to ...

Samsung Biologics, the biopharmaceutical arm of Samsung Group, said on May 26 it had secured two contract manufacturing deals worth a combined 4.4 trillion won ($320 million) with European and Asian ...

Spinning off Samsung Bioepis Samsung Biologics announced on Thursday that it will create a new holding company, Samsung Epis Holdings, through a simple division. This is to separate the CDMO business ...

In 2022, Samsung Biologics acquired Biogen’s remaining shares for $2.3 billion. “This split reflects our decision to enhance competitiveness by responding swiftly to global changes and ...

Samsung Biologics announced on the 22nd that it would establish a new holding company, "Samsung Bioepis Holdings," through a simple spin-off partitioning method, completely separating its contract ...

CDMO weighs plan to build a 6th plant The decision to split the businesses comes in response to industry concerns about conflicts of interest between Samsung Biologics—which contracts with many ...